PASELLO, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.601
AS - Asia 5.458
EU - Europa 3.340
AF - Africa 1.401
SA - Sud America 1.340
OC - Oceania 143
Continente sconosciuto - Info sul continente non disponibili 57
Totale 21.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.856
SG - Singapore 2.066
CN - Cina 861
BR - Brasile 844
IT - Italia 674
HK - Hong Kong 654
VN - Vietnam 421
DE - Germania 302
FI - Finlandia 239
SE - Svezia 197
PL - Polonia 195
GB - Regno Unito 168
FR - Francia 156
IN - India 150
NL - Olanda 145
RU - Federazione Russa 141
AR - Argentina 113
MX - Messico 85
TR - Turchia 76
ID - Indonesia 73
IQ - Iraq 70
BJ - Benin 68
AT - Austria 67
KR - Corea 67
IE - Irlanda 62
EC - Ecuador 60
AO - Angola 58
PE - Perù 55
UA - Ucraina 55
ZA - Sudafrica 53
PY - Paraguay 52
RS - Serbia 52
ES - Italia 51
CZ - Repubblica Ceca 49
JP - Giappone 49
CI - Costa d'Avorio 48
CY - Cipro 48
CA - Canada 47
IL - Israele 46
PK - Pakistan 46
BE - Belgio 45
CM - Camerun 45
CR - Costa Rica 45
DZ - Algeria 45
MA - Marocco 44
PT - Portogallo 44
SA - Arabia Saudita 44
SN - Senegal 44
TN - Tunisia 44
UZ - Uzbekistan 44
EG - Egitto 43
AE - Emirati Arabi Uniti 42
AL - Albania 42
AZ - Azerbaigian 42
VE - Venezuela 42
CH - Svizzera 41
GP - Guadalupe 41
PA - Panama 41
PS - Palestinian Territory 41
BA - Bosnia-Erzegovina 40
CO - Colombia 40
DO - Repubblica Dominicana 40
JO - Giordania 40
LV - Lettonia 40
BY - Bielorussia 39
GH - Ghana 39
MD - Moldavia 39
PR - Porto Rico 39
UY - Uruguay 39
RO - Romania 38
YT - Mayotte 38
LC - Santa Lucia 36
NO - Norvegia 36
RW - Ruanda 36
ZM - Zambia 36
BD - Bangladesh 35
BZ - Belize 35
LB - Libano 35
NZ - Nuova Zelanda 35
SO - Somalia 35
CG - Congo 34
GA - Gabon 34
KE - Kenya 34
KZ - Kazakistan 34
ME - Montenegro 34
MK - Macedonia 34
TT - Trinidad e Tobago 34
AU - Australia 33
BO - Bolivia 33
HR - Croazia 33
LY - Libia 33
MZ - Mozambico 33
PH - Filippine 33
SI - Slovenia 33
XK - ???statistics.table.value.countryCode.XK??? 33
YE - Yemen 33
CL - Cile 32
HN - Honduras 32
BG - Bulgaria 31
CU - Cuba 31
Totale 19.789
Salva come PNG Salva come JPEG
Città #
Fairfield 1.251
Ashburn 1.185
Singapore 1.090
Woodbridge 651
Chandler 620
Hong Kong 617
Houston 476
Cambridge 402
Seattle 402
Wilmington 347
Santa Clara 313
Beijing 297
Ann Arbor 287
Boardman 186
San Diego 180
Los Angeles 167
Padova 153
Ho Chi Minh City 144
Bytom 137
Helsinki 115
Princeton 110
Chicago 105
New York 105
Medford 102
Hefei 93
Munich 92
Roxbury 82
Des Moines 80
Hanoi 80
São Paulo 75
Cotonou 65
Buffalo 61
Lappeenranta 53
London 50
Nuremberg 49
Abidjan 47
Milan 47
Luanda 46
Seoul 46
Dakar 43
Dublin 43
Turku 42
Tashkent 40
Amman 39
Baku 37
Stockholm 37
Dong Ket 36
Kigali 36
Lusaka 36
Panama City 36
Redondo Beach 36
Castries 35
Montevideo 35
Salt Lake City 35
San José 35
Riga 34
Vienna 34
Accra 33
Dallas 33
Libreville 33
Brooklyn 32
Guangzhou 32
Lima 32
Conakry 31
Istanbul 31
Warsaw 31
Baghdad 30
Kampala 30
Nanjing 30
Ulan Bator 30
Nairobi 29
Dushanbe 28
Frankfurt am Main 28
Kingstown 28
Nouakchott 28
Podgorica 28
Brazzaville 27
Havana 27
Phnom Penh 27
Yerevan 27
Antananarivo 26
Bamako 26
Nassau 26
Auckland 25
Bishkek 25
Limassol 25
Noumea 25
Tallinn 25
Andorra la Vella 24
Montreal 24
Rio de Janeiro 24
Rome 24
Bridgetown 23
Gaborone 23
Johannesburg 23
Lilongwe 23
Minsk 23
Tokyo 23
Vientiane 23
Amsterdam 22
Totale 12.244
Salva come PNG Salva come JPEG
Nome #
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 244
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 241
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib 235
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 232
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 223
Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections? 217
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal 215
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time 206
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 204
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 201
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model 199
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 199
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 198
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 197
COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. 196
Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment 193
Metabolic rewiring and redox alterations in malignant pleural mesothelioma 192
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists 191
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 191
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 190
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 182
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 179
Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature 179
18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy 179
Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience 179
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial 179
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 177
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. 176
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 175
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 174
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 173
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data 172
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 172
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 168
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 167
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 166
Liquid biopsy in malignant pleural mesothelioma: State of the art, pitfalls, and perspectives 165
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 165
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 165
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 164
Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab 158
Effects of sulfonylureas on tumor growth: A review of the literature 157
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer 155
Synergistic antitumor activity of recombinant human Apo2L/Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma 154
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience 153
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 152
A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients 151
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 151
Squamous cell carcinomas of the lung and of the head and neck: New insights on molecular characterization 150
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection 149
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. 148
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 148
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 148
Lobectomy with artery reconstruction and pneumonectomy for NSCLC: a propensity score weighting study 147
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 147
Results of surgical resection after induction chemoradiation for Pancoast tumours 146
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment 144
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 144
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 141
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) 140
Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel) 140
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 137
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 137
Diagnostic challenges in epithelioid pleural mesothelioma: Case series with support from electron microscopy 137
Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma 136
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 135
The rarest of rare thymic lesions: A 10-year surgical pathology experience 135
Mesothelin-targeted agents in mesothelioma 132
realpse patterns and tailored treatment strategies for malignant pleural mesothelioma recurrence after multimodality therapy 132
Vascular involvement in thymic epithelial tumors: Surgical and oncological outcomes 132
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology 131
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 130
DNA copy number alterations correlate with survival in esophageal adenocarcinoma patients. 130
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 129
Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC) 128
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer 128
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 127
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer 126
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer 125
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience 124
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment 124
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients 123
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors 123
EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience 123
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 123
A pathological complete response after preoperative chemotherapy with carboplatin and pemetrexed in malignant pleural mesothelioma: A case report. 123
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies 122
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: A randomized phase II study 122
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 121
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 120
PET/CT And The Response To Immunotherapy In Lung Cancer 119
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection† 118
Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall 118
Additional Value of PET and CT Image-Based Features in the Detection of Occult Lymph Node Metastases in Lung Cancer: A Systematic Review of the Literature 117
DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma 116
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 116
Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC 115
Vascular/epithelial changes as late sequelae after recovery from SARS-COV-2 infection: an in-vivo comparative study 115
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab 114
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome 113
Totale 15.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.887
article - articoli 69.466
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 630
Totale 140.983
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.541 0 0 0 0 33 141 510 181 208 180 96 192
2021/20222.001 118 221 191 58 161 280 228 88 138 75 118 325
2022/20231.236 211 162 47 165 146 148 16 74 157 23 74 13
2023/20241.011 42 109 112 95 68 165 75 65 70 52 82 76
2024/20254.399 19 367 248 157 539 131 164 362 345 232 698 1.137
2025/20269.434 991 1.397 2.518 3.056 1.472 0 0 0 0 0 0 0
Totale 21.612